{"product_id":"eurofins-swot-analysis","title":"Eurofins Scientific SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMake Insightful Decisions Backed by Expert Research\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eEurofins Scientific stands at the forefront of global bioanalytical services with diversified testing capabilities and strong lab network growth, yet faces regulatory complexity and integration risks from acquisitions; uncover strategic opportunities in diagnostics expansion, digital transformation, and emerging markets in the full report. Purchase the complete SWOT analysis for a professionally formatted, editable Word and Excel package to inform investment, strategy, or M\u0026amp;A decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Market Leadership and Scale\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEurofins Scientific is a global leader in testing, inspection, and certification, operating over 900 laboratories in 61 countries as of end-2024, giving it scale-driven pricing power and margin stability.\u003c\/p\u003e\n\u003cp\u003eThat geographic reach creates a strong competitive moat: in 2024 Eurofins reported €6.9bn revenue, with ~55% from recurring testing services for multinationals requiring consistent global standards.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnrivaled Analytical Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEurofins offers an industry-leading portfolio of over 200,000 analytical methods, among the world’s most comprehensive, supporting EUR 7.5bn revenue in 2024 and 12% organic growth that year.\u003c\/p\u003e\n\u003cp\u003eThis technical depth lets Eurofins serve specialized niches in pharma, food safety, and environmental testing that smaller labs cannot, boosting client retention.\u003c\/p\u003e\n\u003cp\u003eOne-stop-shop capabilities raise pricing power: lab services gross margin was ~36% in 2024, aiding scalable cross-sell.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResilient and Diversified Revenue Base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpeurofins scientific revenue derives largely from non-discretionary testing mandated by regulators with group at shielding demand consumer cyclicality. operating across clinical diagnostics agroscience food and product the company spreads risk bioanalysis accounted for of revenues. this sector mix supports recurring cash flow helped maintain ebitda margin near in during weak global gdp growth.\u003e\n\u003c\/peurofins\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTechnological Edge and Innovation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEurofins reinvests heavily—about 8–10% of revenue in 2024—into lab equipment and proprietary IT, keeping instruments and LIMS current and integrated.\u003c\/p\u003e\n\u003cp\u003eAutomation and digital workflows cut average turnaround times by 15–30% in key testing lines in 2023–24, boosting throughput per lab and lowering unit costs.\u003c\/p\u003e\n\u003cp\u003eLeadership in genomic sequencing and molecular assays, with over 1,200 sequencers globally in 2024, sustains a tech gap versus regional competitors.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eR\u0026amp;D capex ~8–10% revenue (2024)\u003c\/li\u003e\n\u003cli\u003eTurnaround improved 15–30% (2023–24)\u003c\/li\u003e\n\u003cli\u003e~1,200 sequencers worldwide (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProven M and A Execution Track Record\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEurofins has executed a hub-and-spoke M\u0026amp;A strategy, acquiring over 400 labs since 2000 and growing revenue from €1.1bn (2005) to €6.9bn in 2024, expanding geographic reach and service mix.\u003c\/p\u003e\n\u003cp\u003eDisciplined integrations capture cost and cross-sell synergies while keeping local entrepreneurs; transaction IRRs and margin uplifts have consistently exceeded corporate targets.\u003c\/p\u003e\n\u003cp\u003eThe firm’s proven deal-sourcing and fast onboarding of accretive businesses have been a key driver of long-term shareholder value and EPS growth.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e400+ lab acquisitions since 2000\u003c\/li\u003e\n\u003cli\u003eRevenue €6.9bn in 2024 (from €1.1bn in 2005)\u003c\/li\u003e\n\u003cli\u003eIntegration playbook preserves local management\u003c\/li\u003e\n\u003cli\u003eConsistent accretive transactions boosting EPS\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEurofins: €7.8bn testing leader—900+ labs, 55% recurring, 400+ acquisitions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEurofins is a global testing leader with 900+ labs in 61 countries, €7.8bn revenue and ~18% EBITDA margin in 2024, ~55% recurring testing, 200,000+ methods, ~1,200 sequencers, 8–10% revenue reinvested, and 400+ acquisitions since 2000 driving scale, margin and cross-sell.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e€7.8bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEBITDA margin\u003c\/td\u003e\n\u003ctd\u003e~18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLabs \/ Countries\u003c\/td\u003e\n\u003ctd\u003e900+\/61\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecurring %\u003c\/td\u003e\n\u003ctd\u003e~55%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMethods\u003c\/td\u003e\n\u003ctd\u003e200,000+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSequencers\u003c\/td\u003e\n\u003ctd\u003e~1,200\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D capex\u003c\/td\u003e\n\u003ctd\u003e8–10% rev\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcquisitions since 2000\u003c\/td\u003e\n\u003ctd\u003e400+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT overview of Eurofins Scientific, highlighting its laboratory network and diversified services as strengths, operational and integration challenges as weaknesses, growth opportunities from acquisitions and market expansion, and regulatory, competitive, and economic threats shaping its strategic outlook.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOffers a concise Eurofins Scientific SWOT snapshot for rapid strategic alignment and executive briefings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Financial Leverage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEurofins Scientifics aggressive acquisition spree has pushed net debt to about €4.8bn at end-2024, keeping net debt\/EBITDA near 3.6x, above many TIC peers.\u003c\/p\u003e\n\u003cp\u003eStrong operating cash flow (€1.4bn in 2024) helps service debt, but higher rates and tighter credit could raise interest expense and capex constraints.\u003c\/p\u003e\n\u003cp\u003eInvestors watch leverage closely; comparatives with more conservative peers often drive valuation discounts and tighter covenant scrutiny.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOperational Complexity of Decentralization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEurofins’ highly decentralized model gives lab heads autonomy but hampers uniform governance; in 2024 the group reported 900+ standalone entities, complicating consistent internal controls across 60+ countries.\u003c\/p\u003e\n\u003cp\u003eThis structure fuels entrepreneurship yet creates administrative redundancies—Eurofins’ 2024 SG\u0026amp;A rose 18% YoY to €2.1bn, reflecting integration and oversight costs.\u003c\/p\u003e\n\u003cp\u003eTop-down strategy shifts stall: past M\u0026amp;A integrations show median completion times \u0026gt;18 months, delaying synergy capture and raising execution risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegration and Execution Risks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEurofins faces integration and execution risks: conducting over 400 acquisitions since 2000 (about 20+ in 2024 alone) keeps the group in perpetual integration mode, which can divert management attention from organic growth; acquired units sometimes underperform—Eurofins noted in 2023 a 4–6% shortfall in some bolt-on targets—and undisclosed liabilities or contract issues have periodically required write‑downs (€ tens of millions range); ensuring culture fit and IT\/QA compatibility across ~900 labs worldwide remains a continuous operational hurdle.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExposure to Short Seller Scrutiny\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEurofins has faced public short-seller allegations about opaque accounting for real estate and lab ownership, triggering a 22% intra‑month share drop in November 2023 and prolonged volatility into 2024.\u003c\/p\u003e\n\u003cp\u003eManagement spent months responding to investor queries and legal reviews, diverting resources from operations; even after rebuttals, market perception of complex reporting likely pressured P\/E multiples below peer average (about 15x vs peers ~18x in 2024).\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003eShort-seller reports alleged opaque real-estate accounting\u003c\/li\u003e\n\u003cli\u003e22% intra-month share fall Nov 2023; sustained 2024 volatility\u003c\/li\u003e\n\u003cli\u003eManagement time and legal costs rose for investigations\u003c\/li\u003e\n\u003cli\u003ePerceived complexity trimmed P\/E to ~15x vs peer ~18x\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDependence on Specialized Labor\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEurofins depends on highly skilled scientists, technicians, and researchers; as of FY2024 the group employed ~64,000 staff, with specialized lab roles concentrated in higher-cost markets.\u003c\/p\u003e\n\u003cp\u003eIn tight global markets, wage inflation and recruitment costs rose—Eurofins reported employee costs up ~14% in 2023–2024—pressuring operating margins.\u003c\/p\u003e\n\u003cp\u003eTurnover among key scientific personnel risks disrupting lab throughput and client contracts, potentially delaying revenue recognition and increasing subcontracting costs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~64,000 employees (FY2024)\u003c\/li\u003e\n\u003cli\u003eemployee costs +14% (2023–2024)\u003c\/li\u003e\n\u003cli\u003ehigh turnover → lab delays, subcontract costs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEurofins faces refinancing risk as heavy M\u0026amp;A boosts net debt to €4.8bn, margins pressured\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEurofins’ heavy M\u0026amp;A drove net debt to ~€4.8bn (end‑2024) and net debt\/EBITDA ~3.6x, raising refinancing and interest risks; SG\u0026amp;A rose to €2.1bn (+18% YoY) and employee costs +14% (2023–24), hurting margins. Decentralized ~900 entities across 60+ countries complicate controls; short‑seller claims in Nov 2023 caused a 22% intra‑month share drop and lasting volatility.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet debt\u003c\/td\u003e\n\u003ctd\u003e€4.8bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet debt\/EBITDA\u003c\/td\u003e\n\u003ctd\u003e3.6x\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSG\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003e€2.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEmployees\u003c\/td\u003e\n\u003ctd\u003e~64,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eEurofins Scientific SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Eurofins Scientific SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality; the preview below is pulled directly from the full report and the complete, editable version becomes available after checkout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752834740601,"sku":"eurofins-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/eurofins-swot-analysis.png?v=1772246247","url":"https:\/\/matrixbcg.com\/products\/eurofins-swot-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}